eton
pharmaceuticals
announces
acceptance
filing
new
drug
application
zonisamide
oral
suspension
deer
park
globe
newswire
eton
pharmaceuticals
inc
nasdaq
eton
specialty
pharmaceutical
company
focused
developing
commercializing
innovative
treatments
rare
pediatric
diseases
today
announced
food
drug
administration
fda
accepted
filing
company
new
drug
application
nda
zonisamide
oral
suspension
application
assigned
prescription
drug
user
fee
act
pdufa
date
may
application
submitted
treatment
partial
seizures
patients
epilepsy
zonisamide
one
eton
three
oral
liquid
product
candidates
submitted
fda
three
product
candidates
expected
approved
launched
eton
pharmaceuticals
eton
pharmaceuticals
specialty
pharmaceutical
company
focused
developing
commercializing
innovative
treatments
rare
pediatric
diseases
company
currently
owns
receives
royalties
three
approved
products
including
sprinkle
preservative
free
six
additional
products
pipeline
including
five
submitted
fda
statements
statements
contained
press
release
regarding
matters
historical
facts
statements
within
meaning
private
securities
litigation
reform
act
including
statements
associated
expected
ability
eton
undertake
certain
activities
accomplish
certain
goals
objectives
statements
include
limited
statements
regarding
eton
business
strategy
eton
plans
develop
commercialize
product
candidates
safety
efficacy
eton
product
candidates
eton
plans
expected
timing
respect
regulatory
filings
approvals
size
growth
potential
markets
eton
product
candidates
statements
subject
risks
uncertainties
actual
results
may
differ
materially
expressed
implied
statements
words
believes
anticipates
plans
expects
intends
goal
potential
similar
expressions
intended
identify
statements
statements
based
upon
eton
current
expectations
involve
assumptions
may
never
materialize
may
prove
incorrect
actual
results
timing
events
could
differ
materially
anticipated
statements
result
various
risks
uncertainties
include
without
limitation
risks
associated
process
discovering
developing
commercializing
drugs
safe
effective
use
human
therapeutics
endeavor
building
business
around
drugs
risks
concerning
eton
development
programs
financial
position
described
additional
detail
eton
filings
securities
exchange
commission
statements
contained
press
release
speak
date
made
eton
undertakes
obligation
update
statements
reflect
events
occur
circumstances
exist
date
made
company
contact
david
krempa
dkrempa
